Niagen Bioscience (NAGE) Accumulated Expenses (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Accumulated Expenses data on file, last reported at $7.6 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $7.6 million, down 15.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.6 million (down 15.79% YoY), and the FY2025 annual result was $7.7 million, down 1.22% from the prior year.
• Accumulated Expenses eased to $7.6 million in Q1 2026 per NAGE's latest filing, from $7.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $10.5 million in Q1 2024 and troughed at $6.7 million in Q2 2022.
• A 5-year average of $8.3 million and a median of $8.1 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 36.07% in 2023, then declined 17.66% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $7.3 million in 2022, then increased by 29.39% to $9.5 million in 2023, then dropped by 17.66% to $7.8 million in 2024, then retreated by 1.22% to $7.7 million in 2025, then dropped by 1.31% to $7.6 million in 2026.
• Business Quant data shows NAGE's Accumulated Expenses at $7.6 million in Q1 2026, $7.7 million in Q4 2025, and $8.7 million in Q3 2025.